EU/3/17/1879

About

This medicine is now known as Angiotensin 1-7.

On 20 June 2017, orphan designation (EU/3/17/1879) was granted by the European Commission to Envigo Pharma Consulting Limited, United Kingdom, for Asp-Arg-Val-Tyr-Ile-His-Pro (also known as TXA127) for the treatment of epidermolysis bullosa.

The sponsorship was transferred to Envigo CRS S.A., Spain, in April 2019.

The sponsorship was transferred to Rapport Global Strategic Services Ireland Limited in January 2020.

Key facts

Active substance
Asp-Arg-Val-Tyr-Ile-His-Pro (Angiotensin 1-7)
Disease / condition
Treatment of epidermolysis bullosa
Date of first decision
20/06/2017
Outcome
Positive
EU designation number
EU/3/17/1879

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Rapport Global Strategic Services Ireland Limited
22 Northumberland Road 
Ballsbridge
Dublin 4
Ireland 
Tel: +353 1 671 5 564
E-mail: support@rapportss.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating